ArticleAnnals of surgical oncology2014
FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.
Article in Annals of surgical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Novel Molecular Subtyping Predicts Locoregional Recurrence in Triple-negative Breast Cancer.Advances in radiation oncology · 2025Article
- Amogel: a multi-omics classification framework using associative graph neural networks with prior knowledge for biomarker identification.BMC bioinformatics · 2025Article
- USP10 promotes pancreatic ductal adenocarcinoma progression by attenuating FOXC1 protein degradation to activate the WNT signaling pathway.International journal of biological sciences · 2024Article
- Article
- FOXC1 Negatively Regulates DKK1 Expression to Promote Gastric Cancer Cell Proliferation Through Activation of Wnt Signaling Pathway.Frontiers in cell and developmental biology · 2021Article
- Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis.Frontiers in oncology · 2021Review
- FOXCUT Promotes the Proliferation and Invasion by Activating FOXC1/PI3K/AKT Pathway in Colorectal Cancer.Cancer management and research · 2020Article
- Forkhead box C1 promotes metastasis and invasion of non-small cell lung cancer by binding directly to the lysyl oxidase promoter.Cancer science · 2019Article
- The Diverse Consequences ofCancers · 2019Review
- Meta-analysis of the likelihood of FOXC1 expression in early- and late-stage tumors.Oncotarget · 2018Article
- Silencing FOXC1 inhibits growth and migration of human oral squamous cell carcinoma cells.Experimental and therapeutic medicine · 2018Article
- Forkhead box protein C1 promotes cell proliferation and invasion in human cervical cancer.Molecular medicine reports · 2018Article
- Research progress on the forkhead box C1.Oncotarget · 2018Review
- Characterization of primary human mammary epithelial cells isolated and propagated by conditional reprogrammed cell culture.Oncotarget · 2018Article
- FOXC1, the new player in the cancer sandbox.Oncotarget · 2018Review
- Long noncoding RNA SNHG6 promotes the progression of colorectal cancer through sponging miR-760 and activation of FOXC1.OncoTargets and therapy · 2018Article
- FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles.Therapeutic advances in medical oncology · 2017Review
- FOXC1: an emerging marker and therapeutic target for cancer.Oncogene · 2017Review
- Identification of EGF-NF-κB-FOXC1 signaling axis in basal-like breast cancer.Cell communication and signaling : CCS · 2017Article
- FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.Cancer chemotherapy and pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHuman basal-like breast cancer (BLBC) has a poor prognosis and is often identified by expression of the epidermal growth factor receptor (EGFR). BLBC remains a major clinical challenge because its pathogenesis is not well understood, thus hindering efforts to develop targeted therapies. Recent data implicate the forkhead box C1 (FOXC1) transcription factor as an important prognostic biomarker and functional regulator of BLBC, but its regulatory mechanism and impact on BLBC tumorigenesis remain unclear.
methodsThe association between FOXC1 and EGFR expression in human breast cancer was examined by immunohistochemistry in formalin-fixed tissues and analysis of the TCGA database. The regulation of FOXC1 by EGFR activation was investigated in MDA-MB-468 cells using immunoblotting, qRT-PCR, and luciferase activity assays. This EGFR effect on FOXC1 expression was confirmed using the MDA-MB-468 xenograft model.
resultsBoth FOXC1 mRNA and protein levels significantly correlated with EGFR expression in human breast tumors. EGFR activation induced FOXC1 transcription through the ERK and Akt pathways in BLBC. EGFR inhibition in vivo reduced FOXC1 expression in xenograft tumors. We also found that FOXC1 knockdown impaired the effects of EGF on BLBC cell proliferation, migration, and invasion.
conclusionsOur findings uncover a novel EGFR-FOXC1 signaling axis critical for BLBC cell functions, supporting the notion that intervention in the FOXC1 pathway may provide potential modalities for BLBC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.